Krystal Biotech, Inc. (KRYS)
NASDAQ: KRYS · Real-Time Price · USD
168.06
-1.06 (-0.63%)
Apr 25, 2025, 4:00 PM EDT - Market closed
Krystal Biotech Stock Forecast
Stock Price Forecast
The 7 analysts with 12-month price forecasts for Krystal Biotech stock have an average target of 220, with a low estimate of 206 and a high estimate of 245. The average target predicts an increase of 30.91% from the current stock price of 168.06.
Analyst Consensus: Strong Buy
* Price targets were last updated on Mar 5, 2025.
Analyst Ratings
The average analyst rating for Krystal Biotech stock from 7 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 4 | 4 | 3 | 4 | 4 |
| Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 7 | 7 | 6 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jefferies | Jefferies | Strong Buy Initiates $245 | Strong Buy | Initiates | $245 | +45.78% | Mar 5, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $221 | Strong Buy | Reiterates | $221 | +31.50% | Feb 28, 2025 |
| Citigroup | Citigroup | Hold Maintains $206 → $215 | Hold | Maintains | $206 → $215 | +27.93% | Feb 20, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $215 | Buy | Reiterates | $215 | +27.93% | Feb 20, 2025 |
| Chardan Capital | Chardan Capital | Strong Buy Maintains $212 → $218 | Strong Buy | Maintains | $212 → $218 | +29.72% | Feb 20, 2025 |
Financial Forecast
Revenue This Year
466.37M
from 290.52M
Increased by 60.53%
Revenue Next Year
679.58M
from 466.37M
Increased by 45.72%
EPS This Year
7.15
from 3.00
Increased by 138.31%
EPS Next Year
11.32
from 7.15
Increased by 58.30%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 504.8M | 901.7M | 1.2B | ||
| Avg | 466.4M | 679.6M | 854.2M | ||
| Low | 423.5M | 499.1M | 530.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 73.8% | 93.4% | 80.6% | ||
| Avg | 60.5% | 45.7% | 25.7% | ||
| Low | 45.8% | 7.0% | -22.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 8.77 | 16.94 | 24.81 | ||
| Avg | 7.15 | 11.32 | 15.10 | ||
| Low | 5.41 | 6.11 | 8.32 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 192.3% | 136.9% | 119.2% | ||
| Avg | 138.3% | 58.3% | 33.5% | ||
| Low | 80.3% | -14.6% | -26.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.